Biotech Values

[iwfal]

ZGEN/BMY -

First, Lambda is not the only interferon drug vying to supersede Pegasys and Pegintron in HCV.* Locteron, a Pegasys biosimilar, is further advanced than Lambda and is backed by the well-financed venture, Biolex. It’s likely that other Pegasys biosimilars will enter the market during the current decade, pressuring prices for all of the HCV interferons. In short, the notion that Lambda will usurp the sales now shared by Pegasys and Pegintron without a fight strikes me as naïve.

See my response to this argument here:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54294454